843 related articles for article (PubMed ID: 27730528)
1. Body mass index and menopausal disorders during menopause affect vasomotor symptoms of postmenopausal Japanese breast cancer patients treated with anastrozole: a prospective multicenter cohort study of patient-reported outcomes.
Tane K; Egawa C; Takao S; Yamagami K; Miyashita M; Baba M; Ichii S; Konishi M; Kikawa Y; Minohata J; Okuno T; Miyauchi K; Wakita K; Suwa H; Hashimoto T; Nishino M; Matsumoto T; Hidaka T; Konishi Y; Sakoda Y; Miya A; Kishimoto M; Nishikawa H; Kono S; Kokufu I; Sakita I; Kitatsuji K; Oh K; Akazawa K; Miyoshi Y
Breast Cancer; 2017 Jul; 24(4):528-534. PubMed ID: 27730528
[TBL] [Abstract][Full Text] [Related]
2. Risk factors for joint symptoms in postmenopausal Japanese breast cancer patients treated with anastrozole: a prospective multicenter cohort study of patient-reported outcomes.
Egawa C; Hirokaga K; Takao S; Yamagami K; Miyashita M; Baba M; Ichii S; Konishi M; Kikawa Y; Minohata J; Okuno T; Miyauchi K; Wakita K; Suwa H; Hashimoto T; Nishino M; Matsumoto T; Hidaka T; Konishi Y; Sakoda Y; Miya A; Mitsunobu M; Nishikawa H; Kono S; Kokufu I; Sakita I; Kitatsuji K; Oh K; Miyoshi Y
Int J Clin Oncol; 2016 Apr; 21(2):262-269. PubMed ID: 26411314
[TBL] [Abstract][Full Text] [Related]
3. Acute effects of tamoxifen and third-generation aromatase inhibitors on menopausal symptoms of breast cancer patients.
Morales L; Neven P; Timmerman D; Christiaens MR; Vergote I; Van Limbergen E; Carbonez A; Van Huffel S; Ameye L; Paridaens R
Anticancer Drugs; 2004 Sep; 15(8):753-60. PubMed ID: 15494636
[TBL] [Abstract][Full Text] [Related]
4. Treatment-associated musculoskeletal and vasomotor symptoms and relapse-free survival in the NCIC CTG MA.27 adjuvant breast cancer aromatase inhibitor trial.
Stearns V; Chapman JA; Ma CX; Ellis MJ; Ingle JN; Pritchard KI; Budd GT; Rabaglio M; Sledge GW; Le Maitre A; Kundapur J; Liedke PE; Shepherd LE; Goss PE
J Clin Oncol; 2015 Jan; 33(3):265-71. PubMed ID: 25512454
[TBL] [Abstract][Full Text] [Related]
5. Treatment-emergent endocrine symptoms and the risk of breast cancer recurrence: a retrospective analysis of the ATAC trial.
Cuzick J; Sestak I; Cella D; Fallowfield L;
Lancet Oncol; 2008 Dec; 9(12):1143-8. PubMed ID: 18976959
[TBL] [Abstract][Full Text] [Related]
6. Vasomotor menopausal symptoms and risk of cardiovascular disease: a pooled analysis of six prospective studies.
Zhu D; Chung HF; Dobson AJ; Pandeya N; Anderson DJ; Kuh D; Hardy R; Brunner EJ; Avis NE; Gold EB; El Khoudary SR; Crawford SL; Mishra GD
Am J Obstet Gynecol; 2020 Dec; 223(6):898.e1-898.e16. PubMed ID: 32585222
[TBL] [Abstract][Full Text] [Related]
7. Obesity, smoking, and risk of vasomotor menopausal symptoms: a pooled analysis of eight cohort studies.
Anderson DJ; Chung HF; Seib CA; Dobson AJ; Kuh D; Brunner EJ; Crawford SL; Avis NE; Gold EB; Greendale GA; Mitchell ES; Woods NF; Yoshizawa T; Mishra GD
Am J Obstet Gynecol; 2020 May; 222(5):478.e1-478.e17. PubMed ID: 31705884
[TBL] [Abstract][Full Text] [Related]
8. Risk factors for joint symptoms in patients enrolled in the ATAC trial: a retrospective, exploratory analysis.
Sestak I; Cuzick J; Sapunar F; Eastell R; Forbes JF; Bianco AR; Buzdar AU;
Lancet Oncol; 2008 Sep; 9(9):866-72. PubMed ID: 18703382
[TBL] [Abstract][Full Text] [Related]
9. Hot flushes and night sweats are associated with coronary heart disease risk in midlife: a longitudinal study.
Herber-Gast G; Brown WJ; Mishra GD
BJOG; 2015 Oct; 122(11):1560-7. PubMed ID: 25377022
[TBL] [Abstract][Full Text] [Related]
10. Prevalence of menopausal symptoms and their influence on adherence in women with breast cancer.
Kyvernitakis I; Ziller V; Hars O; Bauer M; Kalder M; Hadji P
Climacteric; 2014 Jun; 17(3):252-9. PubMed ID: 23805799
[TBL] [Abstract][Full Text] [Related]
11. Vasomotor menopausal symptoms are not associated with incidence of breast cancer in a population-based cohort of mid-aged women.
Johanneke van den Berg M; Mishra GD; van der Schouw YT; Herber-Gast GC
Eur J Cancer; 2014 Mar; 50(4):824-30. PubMed ID: 24361228
[TBL] [Abstract][Full Text] [Related]
12. Q-122 as a novel, non-hormonal, oral treatment for vasomotor symptoms in women taking tamoxifen or an aromatase inhibitor after breast cancer: a phase 2, randomised, double-blind, placebo-controlled trial.
Vrselja A; Latifi A; Baber RJ; Stuckey BGA; Walker MG; Stearns V; Hickey M; Davis SR
Lancet; 2022 Nov; 400(10364):1704-1711. PubMed ID: 36366886
[TBL] [Abstract][Full Text] [Related]
13. Patient-reported outcomes with anastrozole versus tamoxifen for postmenopausal patients with ductal carcinoma in situ treated with lumpectomy plus radiotherapy (NSABP B-35): a randomised, double-blind, phase 3 clinical trial.
Ganz PA; Cecchini RS; Julian TB; Margolese RG; Costantino JP; Vallow LA; Albain KS; Whitworth PW; Cianfrocca ME; Brufsky AM; Gross HM; Soori GS; Hopkins JO; Fehrenbacher L; Sturtz K; Wozniak TF; Seay TE; Mamounas EP; Wolmark N
Lancet; 2016 Feb; 387(10021):857-65. PubMed ID: 26686960
[TBL] [Abstract][Full Text] [Related]
14. Obesity and endocrine therapy: host factors and breast cancer outcome.
Goodwin PJ
Breast; 2013 Aug; 22 Suppl 2():S44-7. PubMed ID: 24074791
[TBL] [Abstract][Full Text] [Related]
15. Specific adverse events are associated with response to exemestane therapy in postmenopausal breast cancer patients: Results from the TEAMIIA study (BOOG2006-04).
Fontein DB; Charehbili A; Nortier JW; Putter H; Kranenbarg EM; Kroep JR; Linn SC; van de Velde CJ
Eur J Surg Oncol; 2017 Apr; 43(4):619-624. PubMed ID: 28017458
[TBL] [Abstract][Full Text] [Related]
16. Menopausal symptoms in breast cancer survivors nearly 6 years after diagnosis.
Davis SR; Panjari M; Robinson PJ; Fradkin P; Bell RJ
Menopause; 2014 Oct; 21(10):1075-81. PubMed ID: 24618765
[TBL] [Abstract][Full Text] [Related]
17. Psychosocial and socioeconomic burden of vasomotor symptoms in menopause: a comprehensive review.
Utian WH
Health Qual Life Outcomes; 2005 Aug; 3():47. PubMed ID: 16083502
[TBL] [Abstract][Full Text] [Related]
18. Estrogen-dependent increase in bone turnover and bone loss in postmenopausal women with breast cancer treated with anastrozole. Prevention with bisphosphonates.
Confavreux CB; Fontana A; Guastalla JP; Munoz F; Brun J; Delmas PD
Bone; 2007 Sep; 41(3):346-52. PubMed ID: 17618847
[TBL] [Abstract][Full Text] [Related]
19. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses.
Baum M; Buzdar A; Cuzick J; Forbes J; Houghton J; Howell A; Sahmoud T;
Cancer; 2003 Nov; 98(9):1802-10. PubMed ID: 14584060
[TBL] [Abstract][Full Text] [Related]
20. The effectiveness of sublingual and topical compounded bioidentical hormone replacement therapy in postmenopausal women: an observational cohort study.
Ruiz AD; Daniels KR
Int J Pharm Compd; 2014; 18(1):70-7. PubMed ID: 24881343
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
